PLRX vs. ANNX, AKRO, FGEN, MORF, GLPG, BHVN, XENE, ARWR, FOLD, and MOR
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Annexon (ANNX), Akero Therapeutics (AKRO), FibroGen (FGEN), Morphic (MORF), Galapagos (GLPG), Biohaven (BHVN), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), and MorphoSys (MOR). These companies are all part of the "pharmaceutical preparations" industry.
Pliant Therapeutics (NASDAQ:PLRX) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.
Pliant Therapeutics received 20 more outperform votes than Annexon when rated by MarketBeat users. However, 73.33% of users gave Annexon an outperform vote while only 71.11% of users gave Pliant Therapeutics an outperform vote.
Pliant Therapeutics' return on equity of -35.08% beat Annexon's return on equity.
97.3% of Pliant Therapeutics shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by insiders. Comparatively, 12.7% of Annexon shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Annexon had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Annexon and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.23 beat Annexon's score of 0.71 indicating that Pliant Therapeutics is being referred to more favorably in the media.
Pliant Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
Annexon has lower revenue, but higher earnings than Pliant Therapeutics.
Pliant Therapeutics currently has a consensus price target of $45.38, indicating a potential upside of 274.07%. Annexon has a consensus price target of $15.33, indicating a potential upside of 217.46%. Given Pliant Therapeutics' higher probable upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than Annexon.
Summary
Pliant Therapeutics beats Annexon on 8 of the 13 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
